Genetically Modified Mesenchymal Stromal/Stem Cells: Application in Critical Illness.
Stem Cell Rev Rep
; 16(5): 812-827, 2020 Oct.
Article
in English
| MEDLINE | ID: covidwho-645185
ABSTRACT
Critical illnesses including sepsis, acute respiratory distress syndromes, ischemic cardiovascular disorders and acute organ injuries are associated with high mortality, morbidity as well as significant health care system expenses. While these diverse conditions require different specific therapeutic approaches, mesenchymal stem/stromal cell (MSCs) are multipotent cells capable of self-renewal, tri-lineage differentiation with a broad range regenerative and immunomodulatory activities, making them attractive for the treatment of critical illness. The therapeutic effects of MSCs have been extensively investigated in several pre-clinical models of critical illness as well as in phase I and II clinical cell therapy trials with mixed results. Whilst these studies have demonstrated the therapeutic potential for MSC therapy in critical illness, optimization for clinical use is an ongoing challenge. MSCs can be readily genetically modified by application of different techniques and tools leading to overexpress or inhibit genes related to their immunomodulatory or regenerative functions. Here we will review recent approaches designed to enhance the therapeutic potential of MSCs with an emphasis on the technology used to generate genetically modified cells, target genes, target diseases and the implication of genetically modified MSCs in cell therapy for critical illness.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Genetic Therapy
/
Critical Illness
/
Mesenchymal Stem Cell Transplantation
/
Mesenchymal Stem Cells
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Stem Cell Rev Rep
Year:
2020
Document Type:
Article
Affiliation country:
S12015-020-10000-1
Similar
MEDLINE
...
LILACS
LIS